RecruitingPHASE1, PHASE2NCT06721013
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- Pirtobrutinib(drug)
- Enrollment
- 58 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford University, Stanford, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
- Ochsner Clinical Foundation, New Orleans, Louisiana, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Clinical Research Alliance, Westbury, New York, United States
- Texas Oncology - Central South, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Texas Oncology Gulf Coast, The Woodlands, Texas, United States
- Nanfang Hospital of Southern Medical University, Guangzhou, China
- Qilu Hospital of Shandong University, Jinan, China
- Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06721013 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation